Australia's Orthocell advances on product approval in Thailand

Orthocell

28/04/2025 04:20

** Shares of regenerative medicine company Orthocell OCC.AX rise 7.8% to A$1.390, set for biggest one-day gain since April 10

** Co says it has received regulatory approval to commence sales for its nerve repair product, Remplir, from the Food and Drug Administration in Thailand

** Stock on track for third consecutive session of gains

** Stock up 2.6% YTD, including current session's moves

(Reporting by Manasi Dasa in Bengaluru)

((Manasi.DasaSundeep@thomsonreuters.com;))